Cargando…

E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines

The CDK/Rb/E2F pathway is commonly disrupted in lung cancer, and thus, it is predicted that blocking the E2F pathway would have therapeutic potential. To test this hypothesis, we have examined the activity of HLM006474 (a small molecule pan-E2F inhibitor) in lung cancer cell lines as a single agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtyka, Courtney A., Chen, Lu, Cress, W. Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022639/
https://www.ncbi.nlm.nih.gov/pubmed/24831239
http://dx.doi.org/10.1371/journal.pone.0096357